A randomized, open label study to compare the effects, in terms of bone mineral density, serum CTX [C-telopeptide of type I collagen] and safety, of monthly Bonviva [ibandronic acid] and weekly alendronate [alendronic acid] in women with post-menopausal osteoporosis

Trial Profile

A randomized, open label study to compare the effects, in terms of bone mineral density, serum CTX [C-telopeptide of type I collagen] and safety, of monthly Bonviva [ibandronic acid] and weekly alendronate [alendronic acid] in women with post-menopausal osteoporosis

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2012

At a glance

  • Drugs Alendronic acid; Ibandronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 24 Mar 2012 Results presented at the 2012 IOF World Congress on Osteoporosis and 11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
    • 20 Aug 2008 Status change from in progress to completed according to Roche protocol registry.
    • 20 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top